Biomedical Ventures

What we do

SCOUT opportunities

We select differential science and technology from prestigious academic groups and research institutions


BUILD value

We support and accelerate the tech transfer process from academic project to company launch


FUND projects

We engage professional investors and close on Seed & Series A rounds in Europe or the US.



What we are experts in:

Technology Transfer

  • Technology & Science Transfer strategy & mentoring
  • IP scouting and analysis
  • Support translational funding applications
  • Negotiate Technology & Science Transfer agreements


  • Entrepreneur-in-Residence program
  • Business plan
  • Incubator benchmarking, strategy and set-up
  • Scouting and managing seed funds


  • Value proposition
  • Business analysis & strategy
  • Project Valuation
  • IP & Licensing
  • Spin-out creation
  • Investment Strategies
  • Business Development

Our core activities

Transforming scientific results into biomedical companies

As a result of in-depth academic scouting process together with life sciences analysis. Chasing Science typically owns a participation as a shareholder in the ventures it builds.

Creating entrepreneurial teams

Our goal is to concentrate highly skilled talents of diverse backgrounds around each new venture that is launched.

Venture management

Chasing Science provides strategic involvement in the ventures co-founded, engaging in activities such as board advisory, market research, team management, product development, financial and legal support, fundraising and various other affairs.

this is rocket science 

this is rocket science 

this is rocket science 

this is rocket science 

this is rocket science 

Meet The Team

We're a multidisciplinary team based in Barcelona, London, Boston and Basel with a passion for science.

“Chasing Science is a place where entrepreneurial talent can grow as a team and as individuals and where scientists can get a variety of benefits from building their companies with us.”

Marc RamisFounder of Chasing Science

Marc Ramis Castelltort, PhD

Marc is passionate about creating novel biomedical ventures. Today, he is focused to launch ventures in the fields of pediatric-first platform technologies, oncology and longevity. He is a co-founder at Rejuveron Senescence Therapeutics AG, Ninevah Therapeutics Ltd and Senolytic Therapeutics Inc. Marc is a Board member or strategic advisor at Aptadel Therapeutics, Retinset Therapeutics, Cyclomed, Gate2Brain, Cebiotex and GeneTether. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder.

Marc was also a founder and Advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. He also supported investments and strategic partnerships at Life Biosciences Inc. in Europe. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc has implemented Entrepreneurs-in-Residence programs at several academic institutions such as IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets).

Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.


Gonzalo Fernández-Miranda, PhD

Gonzalo is a partner at Chasing Science, where he supports the development and creation of new biomedical companies.

He is Head of Operations and Discovery of Ninevah Therapeutics, a portfolio company developing gene therapies for orphan kidney diseases; and interim Head of Operations of Aptadel Therapeutics, another portfolio company developing an RNA-based platform to treat Ewing’s sarcoma and other cancers.

Biochemist by training with a PhD in Molecular Biology, Gonzalo is specialized in RNA biology, gene therapy and molecular oncology. He is the author/co-author of 16 articles with over 800 citations. Gonzalo gained practical entrepreneurial experience thanks to the CaixaImpulse acceleration program (2017) and executive training at ESADE Business School.


Pilar Puig Sàrries, PhD

I’m a doctor in molecular biology who co-founded an NGO in 2012 (Mou), a startup in 2014 (retail industry) and took off for 9 months to travel around South America. When I returned I got involved with investment in startups in the health sector.

After 3 years evaluating investment opportunities, running equity crowdfunding campaigns, preparing contracts, building processes, creating a network of experts… I went to Biocat as innovation project manager of the healthcare accelerator CRAASH Barcelona and other programmes of the European consortium EIT Health.

Some KPIs that define me professionally:
– evaluation of more than 150 investment opportunities
– involved in the investment rounds of 16 startups that together raised more than €12M
– building a community of health experts from 0 to 1400 members


Jordi Naval

I am an experienced and successful biotech CEO (+20 years experience, co-founded 5 companies), with a track record in fundraising, early-stage development, deal-making and M&A.

I am keen to lead the company’s mission and to provide a strategic direction to create a vision of success with a clear execution roadmap.

I am passionate about all the steps of venture building together with the founding scientists and investors, from the first concepts to seed funding, Series A and further. I have raised more than 80 M in private and public funding for different biotechs, and I have contributed to the creation of +300 new high-value jobs.

I have a track record of success in building organizations and leading investor relations, corporate governance, first key hirings, business development and deal-making in Europe and the US. I work well with founding scientists and investors.

I also have extensive hands-on operations experience (discovery, IP, regulatory, manufacturing, preclinical and clinical) across several indications and technologies (oncology, immunology, biologics, gene-therapy), and including AI and Digital.

I am also involved in philanthropic and educational ventures and in the advancement of entrepreneurial ecosystems.

Summary of Key Achievements
– Founded 5 biotech companies as CEO
– Raised +50 M in private funds for different companies (Seed and Series A)
– Raised +30 M in public funding for startups and institutions
– Successfully sold one company and achieved multimillion partnerships with big pharma
– 3 other co-founded companies are now growing in their respective business spaces
– Successfully directly moved 3 biological assets from preclinical to clinical stages
– Built an extensive network of biotech investors and pharma business developers
– Through my CRO company, participated actively in the IND filings of 10+ assets, along with multiple Phase I, II and III clinical programs in multiple indications
– In my TTO and Biocat CEO roles, helped raise +100 M in funding, secured +20 licenses and contributed to +200 M in contract research and partnerships
– Created + 300 jobs, and managed multidisciplinary teams
– Transformed Barcelona biotech ecosystem, attracting investment and talent to the region

Tech Transfer

Esther Riambau

Co-Founder and CEO at Oniria Therapeutics, S.L. and Co-Founder and Board Member at Gate2Brain, S.L. I have over 19 years of experience in Technology Transfer including entrepreneurship, IP licensing, contract research, and business development. I have helped over 150 technological projects, most of them entrepreneurial projects in different technology sectors (medical devices, biotechnology, agro-food, industrial, IT, electronics & sensors, energy & environment, nanotechnology, optics & instrumentation, chemical & drug development) in the initial phases, contributing in business plan elaboration, private and public seed fundraising and team building.

I discovered my vocation during my first job, seeing how the start-up Advancell was created and grew. Since that time I have known that I wanted to create technology-based companies and transfer technology from academy to society.

My background is in technology transfer and my heart is with start-ups!

General Counsel

Javier Merino

Javier Merino is a Founder and Managing Partner of Innovatech Law Firm located in Barcelona. Previously, he had been working with the Barcelona office of Baker & McKenzie, the Barcelona office of Clifford Chance, and the Bristol and London offices of Osborne Clarke.

Javier Merino is actively involved work in the areas of Licensing, Technology Transfer, Intellectual Property, Commercial Law, Venture Capital and Mergers and Acquisitions, Company Law, as well as Data Protection. He is advising in legal matters in such sectors as Life Science, Biotechnology, Pharmaceutical, Nanotechnology, Innovation, Information Technology and Communications, Telecommunications, Software, and some others.


Carmen Ríos

Fluent in six languages, with Spanish and English parents Carmen traverses the diverse cultures in Europe with ease, she is truly international in her outlook. Her drive to create growth in the start up community in Europe and her international outlook naturally brought her to working with Business Leaders. She is passionate about helping businesses contribute to a better world. Believing that companies should balance their economic contribution with a clear social impact. Arguing that the digital revolution offers us the opportunity to change the world in ways that we had never though possible. An opportunity we should grasp with both hands.
Carmen is an expert in digital transformation, having worked in high pressure leadership roles setting up international operations. She fully understands the reach and power that digital offers to deliver services and messages.

Carmen is also an evangelist about Spanish food and never misses the opportunity to share her passion and knowledge about it.


Julián Peña

With more than 15 years of experience in financial and economic management of biotechnology, biomedicine and nanotechnology projects (Celltec-UB, Advancell, Hospital Clinic Foundation, ADmit Therapeutics, Senolytic Therapeutics, Bionure, Accure Tx), he holds a Diploma in Business Sciences from the University of Barcelona and is a professor in the Degree in Biotechnology at the University of Barcelona. Certified mentor by ACCIO, he has managed and coordinated all types of national and European public grants since 2001.

A pediatric-first investment vehicle :
Jana Bioventures

Our vision is to build a leading pediatric-first biomedical platform company that develops novel medicines and digital therapeutics to increase children’s lifespan.

Today, most medicines are approved or in development for adults, not for children. Also, pediatric-based research is not being fully translated to pediatric patients. For kids affected with cancer, mental disorders and rare diseases, it is our responsability do much better.

We are building a platform company with centralized services, leadership & business development, supporting founders and scientists with our entrepreneurial vision and company-building capability.

Jana Biosciences is a pediatric-first biomedical platform holding company.

Visit Jana here :

Where you can find us

We are launching our ventures in Barcelona, London, Boston and Basel with a passion for science.

Do you believe that science can change the world?

Looking forward to work with you



Carrer de la Immaculada, 47
08017 Barcelona, Spain



T: 0034 6...